Patent number: 6933280
Abstract: A pharmaceutical composition, or pharmaceutical agent for treating A? amyloidosis in a patient, having at least one selected laminin peptide or fragment thereof from the group AG73 (SEQ ID NO:1), C-16 (SEQ ID NO:2), A-13 (SEQ ID NO:3), HA3G47 (SEQ ID NO:4), HA3G58 (SEQ ID NO:5), HA3G67 (SEQ ID NO:6), HA3G74 (SEQ ID NO:7), HA3G76 (SEQ ID NO:8), HA3G79 (SEQ ID NO:9), HA3G83 (SEQ ID NO:10), A4G82 (SEQ ID NO:11), A5G15 (SEQ ID NO:12), A5G56 (SEQ ID NO:13), A5G80 (SEQ ID NO:14), A5G81 (SEQ ID NO:15), A5G82 (SEQ ID NO: 16), A5G84 (SEQ ID NO:17), A5G101 (SEQ ID NO:18), and A5G109 (SEQ ID NO:19) (Sequence Group A); and a method for enhancing A? amyloid fibril formation, or of forming amyloid-plaque like deposits in vitro, including incubating A? 1-40 or A? 1-42 with a selected laminin-derived polypeptide from the group A-13 (SEQ ID NO:3), HA3G47 (SEQ ID NO:4), HA3G58 (SEQ ID NO:5), HA3G83 (SEQ ID NO:10), LAM-L (SEQ ID NO:20), A4G10 SEQ ID NO:21), A4G46 (SEQ ID NO:22), A4G47 (SEQ ID NO:23), A4G84 (SEQ ID NO:24), A4G92
Type:
Grant
Filed:
September 24, 2001
Date of Patent:
August 23, 2005
Inventors:
Gerardo Castillo, Alan D. Snow